Press Releases

Receive E-mail Alerts
11 April 2018 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders

LEIDEN, the Netherlands , April 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystrophic

10 April 2018 at 7:00 AM EDT
Summary ToggleProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I editing, Dr. Beal will be instrumental in advancing the

3 April 2018 at 7:00 AM EDT
Summary ToggleProQR to Present at Two Upcoming Conferences

LEIDEN, the Netherlands , April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 10, dystrophic

5 March 2018 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Investor Conference
LEIDEN, the Netherlands , March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
28 February 2018 at 7:00 AM EST
Summary ToggleProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Key updates Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 safety & efficacy trial for QR-110 in children and adults with Leber’s
27 February 2018 at 7:00 AM EST
Summary ToggleProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
LEIDEN, the Netherlands , Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
12 February 2018 at 7:00 AM EST
Summary ToggleFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program
6 February 2018 at 7:00 AM EST
Summary ToggleProQR to Present at Upcoming Scientific Meeting and Investor Conference
LEIDEN, the Netherlands , Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congenital amaurosis 10
8 January 2018 at 7:00 AM EST
Summary ToggleProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
LEIDEN, the Netherlands , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). Under the agreement the two companies will work together to discover novel